Products > OWLiver > Information for physicians > Patents

Patents concerning OWLiver

OWL has developed a blood based test for Steatosis and NASH diagnosis. It is a non-invasive effective method.

 

The identification and validation of metabolic and proteomic markers is the core of this innovative method, which is included on two patents applications presented in 2008:

  • US Patent 8,563,318 B2 & MX 319774

    "METHOD FOR THE DIAGNOSIS OF NON-ALCOHOLIC STEATOHEPATITIS BASED ON A METABOLOMIC PROFILE"

    Selection of a set of metabolites that determines the stage of disease differentiating between healthy controls and patients with steatosis and non-alcoholic steatohepatitis (NASH)

  • US Patent 8,758,992 & Applications PCT/EP 10754349, CA 2775033 & MX /a/2012/003441

    "METHOD FOR THE DIFFERENTIAL DIAGNOSIS OF NON-ALCOHOLIC FATTY LIVER DISEASE BASED ON A METABOLOMIC PROFILE"

    Metabolomic-based diagnostic method that determines the stage of non-alcoholic fatty liver disease, differentiating between patients with simple steatosis and non-alcoholic steatohepatitis (NASH)

OWL is a trading name of
ONE WAY LIVER, S.L
Parque Tecnológico de Bizkaia
Edificio 502 - Planta 0
48160 Derio - Bizkaia - Spain
Phone:
+34 94 431 85 40

With this web OWL intends to provide users with information to better understand their health and their diagnosed illnesses. You should consult with a
qualified physician for diagnosis and for answers to your personal questions/circunstances.
Last update: 07/16/2019

With the collaboration of: